Emerging targets of disease-modifying therapy for systemic sclerosis

Review article: novel oral-targeted therapies in inflammatory bowel disease

(2018) J. R. White et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis

(2018) Christopher P Denton et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review

(2018) Mathilde Thiebaut et al.   AUTOIMMUNITY REVIEWS

Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation

(2018) Keith M. Sullivan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD + Decline

(2018) Mariana G. Tarragó et al.   Cell Metabolism

Chemokines in systemic sclerosis

(2018) Jamie King et al.   IMMUNOLOGY LETTERS

Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy

(2018) Swati Bhattacharyya et al.   IMMUNOLOGY LETTERS

Dendritic cells in systemic sclerosis: Advances from human and mice studies

(2018) Alsya J. Affandi et al.   IMMUNOLOGY LETTERS

Toll Like Receptors in systemic sclerosis: An emerging target

(2018) Steven O’Reilly   IMMUNOLOGY LETTERS

JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis

(2018) Jared S. Kahn et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease

(2018) Hua Xiao et al.   International Journal of Rheumatic Diseases

Mechanosensing and fibrosis

(2018) Daniel J. Tschumperlin et al.   JOURNAL OF CLINICAL INVESTIGATION

Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis

(2018) Tetsuo Toyama et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs

(2018) Massimo Gadina et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The use of JAK inhibitors in the treatment of progressive systemic sclerosis

(2018) S.C. Deverapalli et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The big five in fibrosis: Macrophages, myofibroblasts, matrix, mechanics, and miscommunication

(2018) Pardis Pakshir et al.   MATRIX BIOLOGY

Existing and novel biomarkers for precision medicine in systemic sclerosis

(2018) Peter J. Wermuth et al.   Nature Reviews Rheumatology

Type I interferon in rheumatic diseases

(2018) Theresa L. Wampler Muskardin et al.   Nature Reviews Rheumatology

Cannabinoids for the treatment of rheumatic diseases — where do we stand?

(2018) Daphna Katz-Talmor et al.   Nature Reviews Rheumatology

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

(2018) Keith M. Sullivan et al.   NEW ENGLAND JOURNAL OF MEDICINE

T follicular helper–like cells contribute to skin fibrosis

(2018) Devon K. Taylor et al.   Science Translational Medicine

The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging

(2018) Eduardo N. Chini et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Fibrotic microtissue array to predict anti-fibrosis drug efficacy

(2018) Mohammadnabi Asmani et al.   Nature Communications

Matrix Stiffness: the Conductor of Organ Fibrosis

(2018) Alba Santos et al.   Current Rheumatology Reports

Treatment algorithms for systemic sclerosis according to experts

(2018) Andreu Fernández-Codina et al.   Arthritis & Rheumatology

Double-blind, Randomized, 8-week Placebo-controlled followed by a 16-week open label extension study, with the LPA1 receptor antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis

(2018) Yannick Allanore et al.   Arthritis & Rheumatology

Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus and chronic obstructive pulmonary disease

(2018) Katie Streicher et al.   Arthritis & Rheumatology

Metformin and Autoimmunity: A “New Deal” of an Old Drug

(2018) Francesco Ursini et al.   Frontiers in Immunology

BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance

(2018) Takashi Matsushita et al.   Science Advances

The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy

(2018) Amaal E. Abdulle et al.   Frontiers in Physiology

Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?

(2018) Cosimo Bruni et al.   Frontiers in Immunology

New insights into the genetics and epigenetics of systemic sclerosis

(2018) Chiara Angiolilli et al.   Nature Reviews Rheumatology

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension

(2017) Sean Gaine et al.   EUROPEAN RESPIRATORY JOURNAL

Small molecule therapy for managing moderate to severe psoriatic arthritis

(2017) Luisa Costa et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors

(2017) Miroslava Didiasova et al.   FASEB JOURNAL

Unfolding the pathogenesis of scleroderma through genomics and epigenomics

(2017) Pei-Suen Tsou et al.   JOURNAL OF AUTOIMMUNITY

Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82

(2017) Robert Lafyatis et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Role of B cells in the pathogenesis of systemic sclerosis

(2017) S. Sanges et al.   REVUE DE MEDECINE INTERNE

Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis

(2017) David Lagares et al.   Science Translational Medicine

A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease

(2017) Dimitrios Daoussis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Nrf2 exerts cell-autonomous antifibrotic effects: compromised function in systemic sclerosis and therapeutic rescue with a novel heterocyclic chalcone derivative

(2017) Jun Wei et al.   Translational Research

TGF-β1 Signaling and Tissue Fibrosis

(2017) Kevin K. Kim et al.   Cold Spring Harbor Perspectives in Biology

Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis

(2017) Jörg H. W. Distler et al.   Arthritis & Rheumatology

Belimumab for the Treatment of Early Diffuse Systemic Sclerosis

(2017) Jessica K. Gordon et al.   Arthritis & Rheumatology

CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts

(2017) Minghua Wu et al.   Arthritis & Rheumatology

Association of MicroRNA-618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis

(2017) Marzia Rossato et al.   Arthritis & Rheumatology

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

(2017) Christopher P. Denton et al.   Arthritis & Rheumatology

New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice

(2017) Sayam Dubash et al.   Therapeutic Advances in Chronic Disease

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

(2017) Tobias Puengel et al.   PLoS One

Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease

(2017) Viktor Martyanov et al.   PLoS One

Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways

(2017) Agnieszka P. Grzegorzewska et al.   Scientific Reports

Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis

(2016) Matthieu Ponsoye et al.   ANNALS OF THE RHEUMATIC DISEASES

Update of EULAR recommendations for the treatment of systemic sclerosis

(2016) Otylia Kowal-Bielecka et al.   ANNALS OF THE RHEUMATIC DISEASES

Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review

(2016) Gleb Slobodin et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Cannabinoids, inflammation, and fibrosis

(2016) Robert B. Zurier et al.   FASEB JOURNAL

Macrophages in Tissue Repair, Regeneration, and Fibrosis

(2016) Thomas A. Wynn et al.   IMMUNITY

Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis

(2016) Dinesh Khanna et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial

(2016) D. Khanna et al.   JOURNAL OF RHEUMATOLOGY

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

(2016) Dinesh Khanna et al.   LANCET

Reducing the risk of failure: biomarker-guided trial design

(2016) Michael J. Townsend et al.   NATURE REVIEWS DRUG DISCOVERY

Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins

(2016) Ian B. Robertson et al.   Cold Spring Harbor Perspectives in Biology

SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis

(2016) Kaname Akamata et al.   Oncotarget

Cellular Therapies in Systemic Sclerosis: Recent Progress

(2016) Femke C. C. van Rhijn-Brouwer et al.   Current Rheumatology Reports

Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis

(2016) Athanasios Mavropoulos et al.   Arthritis & Rheumatology

Toll-like Receptor 9 Signaling Is Augmented in Systemic Sclerosis and Elicits Transforming Growth Factor β-Dependent Fibroblast Activation

(2016) Feng Fang et al.   Arthritis & Rheumatology

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

(2016) Donald P Tashkin et al.   Lancet Respiratory Medicine

Redox mechanisms in age-related lung fibrosis

(2016) Ashish Kurundkar et al.   Redox Biology

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

(2015) Yi Zhu et al.   AGING CELL

Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts

(2015) Varvara Kirillov et al.   AMERICAN JOURNAL OF PATHOLOGY

The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis

(2015) Zana Brkic et al.   ANNALS OF THE RHEUMATIC DISEASES

Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis

(2015) Yang Xu et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis

(2015) Katherine G. MacDonald et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein

(2015) Irida Kastrati et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients

(2015) Lisa M. Rice et al.   JOURNAL OF CLINICAL INVESTIGATION

Dissecting fibrosis: therapeutic insights from the small-molecule toolbox

(2015) Carmel B. Nanthakumar et al.   NATURE REVIEWS DRUG DISCOVERY

Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity

(2015) Takashi Matsushita et al.   RHEUMATOLOGY

A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis

(2015) Roberta Goncalves Marangoni et al.   ARTHRITIS RESEARCH & THERAPY

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

(2015) Jessica K. Gordon et al.   ARTHRITIS RESEARCH & THERAPY

The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling

(2015) Jun Wei et al.   Arthritis & Rheumatology

Increased Expression of NAPDH Oxidase 4 in Systemic Sclerosis Dermal Fibroblasts: Regulation by Transforming Growth Factor β

(2015) Sonsoles Piera-Velazquez et al.   Arthritis & Rheumatology

A Reactive Oxygen Species-Mediated Loop Maintains Increased Expression of NADPH Oxidases 2 and 4 in Skin Fibroblasts From Patients With Systemic Sclerosis

(2015) Tatiana Spadoni et al.   Arthritis & Rheumatology

Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation

(2015) Lilian Soto et al.   Frontiers in Immunology

Systemic sclerosis

(2015) Yannick Allanore et al.   Nature Reviews Disease Primers

Cellular Mechanisms of Tissue Fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription

(2014) Pei-Suen Tsou et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis

(2014) Pawel Zerr et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

(2014) Suzana Jordan et al.   ANNALS OF THE RHEUMATIC DISEASES

Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis

(2014) Jacob M. van Laar et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis

(2014) Masataka Kuwana et al.   Modern Rheumatology

Transforming growth factor β—at the centre of systemic sclerosis

(2014) Robert Lafyatis   Nature Reviews Rheumatology

Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis

(2014) Lucille Desallais et al.   ARTHRITIS RESEARCH & THERAPY

Amelioration of Tissue Fibrosis by Toll-like Receptor 4 Knockout in Murine Models of Systemic Sclerosis

(2014) Takehiro Takahashi et al.   Arthritis & Rheumatology

Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis

(2013) Michal Tomcik et al.   ANNALS OF THE RHEUMATIC DISEASES

Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis

(2013) Christian Beyer et al.   ANNALS OF THE RHEUMATIC DISEASES

Review: Evidence That Systemic Sclerosis Is a Vascular Disease

(2013) Marco Matucci-Cerinic et al.   ARTHRITIS AND RHEUMATISM

Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study

(2013) J Baraut et al.   BONE MARROW TRANSPLANTATION

Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development

(2013) Flavia V Castelino et al.   Expert Review of Clinical Immunology

Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

(2013) Tomás Pulido et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis

(2013) Lenny van Bon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence of Anti-RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta-Analysis

(2013) Vincent Sobanski et al.   Arthritis & Rheumatology

Association of Interferon- and Transforming Growth Factor β-Regulated Genes and Macrophage Activation With Systemic Sclerosis-Related Progressive Lung Fibrosis

(2013) Romy B. Christmann et al.   Arthritis & Rheumatology

Recent Developments in Myofibroblast Biology

(2012) Boris Hinz et al.   AMERICAN JOURNAL OF PATHOLOGY

Toll-Like Receptor 4 Signaling Augments Transforming Growth Factor-β Responses

(2012) Swati Bhattacharyya et al.   AMERICAN JOURNAL OF PATHOLOGY

Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

(2012) Muriel Elhai et al.   ANNALS OF THE RHEUMATIC DISEASES

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

(2012) Paul P Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis

(2012) Estrella Garcia Gonzalez et al.   ANNALS OF THE RHEUMATIC DISEASES

Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis

(2012) Xiaochun Liu et al.   ARTHRITIS AND RHEUMATISM

Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis

(2012) Angelika Horn et al.   ARTHRITIS AND RHEUMATISM

JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis

(2012) Clara Dees et al.   ARTHRITIS AND RHEUMATISM

Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells

(2012) Jun Wei et al.   ARTHRITIS AND RHEUMATISM

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

(2012) Gérald Simonneau et al.   EUROPEAN RESPIRATORY JOURNAL

MicroRNA-29: a potential therapeutic target for systemic sclerosis

(2012) Wen-Jia Peng et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

T cells in systemic sclerosis: a reappraisal

(2012) S. O'Reilly et al.   RHEUMATOLOGY

The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy

(2012) Feng Fang et al.   ARTHRITIS RESEARCH & THERAPY

Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma

(2011) Shun Kitaba et al.   AMERICAN JOURNAL OF PATHOLOGY

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

(2011) R. F. Spiera et al.   ANNALS OF THE RHEUMATIC DISEASES

Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease

(2011) Galina S. Bogatkevich et al.   ARTHRITIS AND RHEUMATISM

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center

(2011) Janet Pope et al.   ARTHRITIS AND RHEUMATISM

Role of IL-13 in systemic sclerosis

(2011) Patrizia Fuschiotti   CYTOKINE

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

(2011) Richard K Burt et al.   LANCET

Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities

(2011) Swati Bhattacharyya et al.   Nature Reviews Rheumatology

Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study

(2011) Tatiana S. Rodríguez-Reyna et al.   RHEUMATOLOGY INTERNATIONAL

Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases

(2011) P Szodoray et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease

(2011) Marie-Elise Truchetet et al.   ARTHRITIS RESEARCH & THERAPY

The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study

(2010) M. O. Becker et al.   ANNALS OF THE RHEUMATIC DISEASES

Regulatory T cells (CD4+CD25brightFoxP3+) expansion in systemic sclerosis correlates with disease activity and severity

(2010) Gleb Slobodin et al.   CELLULAR IMMUNOLOGY

Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease

(2010) Maria De Santis et al.   Clinical Respiratory Journal

Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: Possible association with myositis?

(2010) Iman H. Bassyouni et al.   JOINT BONE SPINE

Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression

(2010) Fei Liu et al.   JOURNAL OF CELL BIOLOGY

Dicer Insufficiency and MicroRNA-155 Overexpression in Lupus Regulatory T Cells: An Apparent Paradox in the Setting of an Inflammatory Milieu

(2010) A. A. Divekar et al.   JOURNAL OF IMMUNOLOGY

Increased Production of a Proliferation-inducing Ligand (APRIL) by Peripheral Blood Mononuclear Cells Is Associated with Antitopoisomerase I Antibody and More Severe Disease in Systemic Sclerosis

(2010) M. BIELECKI et al.   JOURNAL OF RHEUMATOLOGY

Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis

(2010) H. Y. Sadik et al.   RHEUMATOLOGY

TLR9 Differentiates Rapidly from Slowly Progressing Forms of Idiopathic Pulmonary Fibrosis

(2010) G. Trujillo et al.   Science Translational Medicine

Rosiglitazone Abrogates Bleomycin-Induced Scleroderma and Blocks Profibrotic Responses Through Peroxisome Proliferator-Activated Receptor-γ

(2009) Minghua Wu et al.   AMERICAN JOURNAL OF PATHOLOGY

STAT4is a genetic risk factor for systemic sclerosis having additive effects withIRF5on disease susceptibility and related pulmonary fibrosis

(2009) P. Dieudé et al.   ARTHRITIS AND RHEUMATISM

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

(2009) Alfiya Akhmetshina et al.   ARTHRITIS AND RHEUMATISM

A TGFβ-Responsive Gene Signature Is Associated with a Subset of Diffuse Scleroderma with Increased Disease Severity

(2009) Jennifer L. Sargent et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Transforming growth factor β as a therapeutic target in systemic sclerosis

(2009) John Varga et al.   Nature Reviews Rheumatology

Scleroderma

(2009) Armando Gabrielli et al.   NEW ENGLAND JOURNAL OF MEDICINE

A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylate

(2009) S Bhattacharyya et al.   ONCOGENE

Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis

(2008) Mirko Manetti et al.   ARTHRITIS AND RHEUMATISM

Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial

(2008) Clarissa E. Vergunst et al.   ARTHRITIS AND RHEUMATISM

Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?

(2007) M T Carulli et al.   ANNALS OF THE RHEUMATIC DISEASES

CXCL10 ( ) and CCL2 ( ) chemokines in systemic sclerosis a longitudinal study

(2007) A. Antonelli et al.   RHEUMATOLOGY